The Biomarker Laboratory offers diagnostic service of biomarkers of Alzheimer’s disease form blood (pTau217) and CSF (beta-amyloid 42, Tau, pTau181) and of neurofilament light chain (Nfl) from blood samples. Results from biomarker analysis facilitate correct and early identification of Alzheimer’s disease.

Plasma pTau217 is a novel non-invasive biomarker for Alzheimer’s disease. The blood test is not recommended for individuals under 50 years of age or for asymptomatic individuals. An elevated level of pTau217 is an indication of Alzheimer’s disease-associated changes in the brain, but these changes do not always lead to illness. The blood test can, together with memory studies and other clinical findings, provide support for an Alzheimer’s diagnosis, and it will be up to the attending physician to decide whether the test is needed. The analysis utilizes Fujirebio Lumipulse technology.

Neurofilament light chain (NfLc) measured from blood sample (preferably EDTA-plasma) is a biomarker for nervous system injury. The analysis requires ultrahigh sensitivity, which is offered by Quanterix Simoa (Single molecule array) technology.

Biomarker Laboratory has ISO 15189 accreditation for CSF beta-amyloid 42, Tau and pTau181 analyses (Li-BAm42, Li-Tau, Li-FosTau), which are run using automated immunoassays (Roche Elecsys).

The laboratory also actively conducts scientific research, including the development of Alzheimer’s analytics and studies related to biomarkers for other neurological diseases.

See our pages in Finnish here.

Updated 30.4.2025